John Durkin

John is former Head of Operations for Equity Research at Baird Kailash and Knight Capital Group. He has been running the day-to-day operations at L2 Asset Management since 2014 and is currently head of Operations. He is also an integral part of the Equity Research team. John received his BA from Stonehill College and has passed his CFA level I. He has an overall experience of 13 years in the industry.

April 28, 2026

Low Quality Small-Caps Tear Higher – The Consequences of Late-Stage Capitalism?

October 17, 2025|

“Late Capitalism” [has] two paradigms [that] combine to swamp the efficient, free-market allocation of capital: 1. Crony capitalism and corruption…choke[s] out the rule of law and reduce the extent to which markets are “free.” 2. The transformation of markets from capital-allocation machines to casinos in which finance becomes just another form of gambling. Reasonable people can argue how far down the path we are… but I do not believe anyone would claim that we weren’t on the road.

Could Cisco Systems, Inc (CSCO) Soar Over 100%?

October 3, 2025|

Through its core hardware and software technologies of switching, routing, and wireless, Cisco Systems, Inc. (CSCO) is the clear leader in global computer networking. CSCO’s capabilities have made -- and continue to make -- the company a central player in shaping the operations of the modern internet, including the growing internet of things (IoT) landscape.

The Power of Price & the Case for GIII Apparel Group Ltd (GIII)

September 15, 2025|

Some of our recent work has highlighted growing economic risks, especially in tech and crypto, with signs of a looming profits recession. The pieces document the remarkable grift from vendor finance, preliminary appearances of consumer weakness, inflated valuations, and debt-driven demand.

Uncertainty: The Leading Cause of Illness in Healthcare Investing?

August 22, 2025|

What’s causing the current malaise in healthcare stocks? Returns have been lagging and valuation multiples are lower than the vast majority of stocks in the S&P 500. We doubt everyone has become so much healthier that we no longer need medicines and hospitals. Is this as simple as “Healthcare isn’t Tech”? We don’t think so.

Accountability with KCR: Our Views on Tech Since Our Founding

August 7, 2025|

The research published in this newsletter is organized and authored by a group of fund managers and researchers who have over 90 years of combined experience and have worked together for over 14 years. As long-time readers know, our sister company, L2 Asset Management, runs a collection of long-only as well as long/short products.

Pediatrix Medical Group, Inc (MD)

July 25, 2025|

Pediatrix Medical Group, Inc. (MD) operates a nationwide network of more than 2,300 affiliated physicians who provide neonatal, maternal-fetal, and pediatric specialty care. As of December 31, 2024, 1,335 of MD’s neonatal physician specialists provided clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with complications.

We Have Been Wrong: We are SO Back!

June 20, 2025|

Watching the mega-cap bubble reflate in 2024, the research in this newsletter peppered readers with warnings about the law of large numbers, soaring capital intensity, dubious accounting and vendor financing activities.

Could Evidence Based Investment Processes Predict the Future? AMGN & The Case for KCR’s Fact-Based, Forecast-Free, Investment Methods

June 11, 2025|

Answer: Nobody can predict the future. With that done, let’s revisit a moment of pain for the KCR team. October of 2010 marked the single first ranking list produced by KCR. The top-ranked stocks were a magnificent collection of companies, in our view. Stocks like Lubrizol, Microsoft, Lorillard, Discover Financial and the 8th ranked stock, Eli-Lilly, sat as our highest ranked healthcare name.

Go to Top